AGIOS PHARMACEUTICALS, INC. Quarterly Operating Income (Loss) in USD from Q1 2012 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Agios Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2012 to Q2 2024.
  • Agios Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$106M, a 12.9% decline year-over-year.
  • Agios Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$405M, a 8.14% decline year-over-year.
  • Agios Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$391M, a 0.63% decline from 2022.
  • Agios Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$389M, a 2.81% decline from 2021.
  • Agios Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$378M, a 12.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$405M -$106M -$12.1M -12.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$393M -$92.1M -$1.46M -1.61% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 -$391M -$106M -$7.11M -7.16% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 -$384M -$101M -$9.81M -10.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$375M -$93.7M +$3.94M +4.04% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$379M -$90.6M +$10.5M +10.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 -$389M -$99.2M +$5.66M +5.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 -$395M -$91.1M +$62K +0.07% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$395M -$97.6M -$6.42M -7.04% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$388M -$101M -$9.93M -10.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$378M -$105M -$12.4M -13.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 -$366M -$91.2M -$10.9M -13.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$355M -$91.2M -$7.96M -9.56% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$347M -$91.2M -$4.19M -4.81% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$343M -$92.4M +$13.5M +12.7% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-25
Q3 2020 -$357M -$80.3M +$28.8M +26.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$385M -$83.3M +$30.6M +26.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 -$416M -$87M +$10.5M +10.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q4 2019 -$426M -$106M -$9.57M -9.94% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$417M -$109M -$9.9M -9.98% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 -$407M -$114M -$40.9M -56.1% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 -$366M -$97.5M -$3.47M -3.69% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 -$362M -$96.4M -$6.23M -6.91% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-19
Q3 2018 -$356M -$99.2M -$20.1M -25.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-19
Q2 2018 -$336M -$72.9M +$11.7M +13.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-19
Q1 2018 -$348M -$94M -$27M -40.2% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-19
Q4 2017 -$321M -$90.1M -$32.7M -57% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-14
Q3 2017 -$288M -$79M -$15.5M -24.4% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-14
Q2 2017 -$273M -$84.6M -$28.1M -49.8% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-14
Q1 2017 -$244M -$67M -$43.5M -184% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-14
Q4 2016 -$201M -$57.4M -$16.5M -40.4% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-14
Q3 2016 -$184M -$63.5M -$23M -56.9% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-14
Q2 2016 -$161M -$56.5M -$24.3M -75.7% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-14
Q1 2016 -$137M -$23.6M -$18.4M -354% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-14
Q4 2015 -$119M -$40.9M -$14.2M -53% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-16
Q3 2015 -$105M -$40.5M -$43.7M -1362% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-16
Q2 2015 -$60.8M -$32.1M -$13.8M -75.3% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-16
Q1 2015 -$47M -$5.2M +$7.09M +57.7% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-16
Q4 2014 -$54.1M -$26.7M -$14.5M -118% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-26
Q3 2014 -$39.6M $3.21M +$14.3M Jul 1, 2014 Sep 30, 2014 10-K 2016-02-26
Q2 2014 -$53.9M -$18.3M -$9.8M -115% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-26
Q1 2014 -$44.1M -$12.3M -$5.24M -74.3% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-26
Q4 2013 -$38.9M -$12.2M -$5.74M -88.4% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-24
Q3 2013 -$33.1M -$11.1M -$5.96M -117% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-24
Q2 2013 -$27.2M -$8.53M -$2.4M -39.2% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-24
Q1 2013 -$24.8M -$7.05M -$1.78M -33.9% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-24
Q4 2012 -$23M -$6.5M Oct 1, 2012 Dec 31, 2012 10-K 2014-03-18
Q3 2012 -$5.11M Jul 1, 2012 Sep 30, 2012 10-K 2014-03-18
Q2 2012 -$6.12M Apr 1, 2012 Jun 30, 2012 10-K 2014-03-18
Q1 2012 -$5.26M Jan 1, 2012 Mar 31, 2012 10-K 2014-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.